RT Journal Article
SR Electronic
T1 Is mRankin scale correlated with mTICI? A systematic review and meta-regression on RCTs and registries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.12.21257077
DO 10.1101/2021.05.12.21257077
A1 De Rubeis, Gianluca
A1 Pampana, Enrico
A1 Prosperini, Luca
A1 Fabiano, Sebastiano
A1 Bertaccini, Luca
A1 Anticoli, Sabrina
A1 Saba, Luca
A1 Gasperini, Claudio
A1 Cotroneo, Enrico
YR 2021
UL http://medrxiv.org/content/early/2021/05/17/2021.05.12.21257077.abstract
AB Background and Purpose mTICI ≥2b/3 is one of the strongest positive predictors of mRS ≤2. Quantitative analysis is poorly investigated. Reconcile results from RCT and registries is still a challenge.The purpose was to evaluate the numeric correlation between mTICI≥2b/3 and mRS≤2 in RCT and registries.Methods Literature research was performed on Pubmed for studies in 2015-2020. mTICI, mRS and sample size were recorded. Exclusion criteria were monocentric study, not-human and not-English. Studies quality were assessed with MINORS and RoB2. Meta-logistic and meta-linear regressions were used to correlate mTICI and mRS in both RCTs and registries. Z-test was used for comparing coefficients between RCTs and registries.Results Twenty-six studies were evaluated (13 registries; 14 RCTs) for 24423 patients (21914 from registries [average per registry 1685±1277]; 2509 from RCTs [average per RCT 179±160]). RCTs involved anterior circulation only, 7/13 (53.8%) registries considered also posterior one.The OR of obtaining a mRS≤2 for a singular increased of mTICI ≥2b rate was 1.65 (CI95% 1.22-2.01) for all studies, 1.65 (CI95% 1.10-2.46) for RCTs and 1.50 (CI95% 1.00-2.23) for registries. mTICI≥2b and mRS had a positive correlation with a coefficient of 0.49 (CI95% 0.19-0.80, p=0.001) for all studies, 0.54 (CI95% 0.09-1.00) for RCTs and 0.42 (CI 95% 0.04-0.81) for registries. No differences were found in the coefficients between RCTs and registries (p=0.63; p=0.65; respectively).Conclusions Unitary increased of mTICI≥2b rate correspond to an augment of mRS≤2 by 0.50 (CI95% 0.19-0.89) with OR of obtaining mRS≤2 of 1.65 (CI95% 1.22-2.01), without significantly differences in coefficients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Since it is a systematic review, IRB approval is not necessaryAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSince it is a systematic review, the data were deribed from literature